GlassScriptPhysician profile
Luz V Tastard
NPI 1144313560
$2,264.99
in general payments reported to CMS, 2019-2025
20 companies · $587 in 2025
The $587 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $157 · 2021: $414 · 2022: $263 · 2023: $259 · 2024: $304 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.79 | 2021-2025 | Botox |
| Merz Pharmaceuticals, LLC | $359.47 | 2021-2025 | Xeomin |
| Grt US Holding, INC. | $124.39 | 2020-2021 | |
| Piramal Critical Care | $100.20 | 2019-2020 | |
| Merz North America, INC. | $86.57 | 2019-2020 | |
| Medtronic, INC. | $81.19 | 2024 | Synchromedii |
| Biohaven Pharmaceuticals, INC. | $78.77 | 2021 | |
| Saol Therapeutics INC. | $77.12 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $38.99 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $38.87 | 2019-2022 | |
| Horizon Therapeutics Plc | $30.53 | 2019 | |
| Amgen INC. | $29.33 | 2021 | |
| Impel Pharmaceuticals INC. | $27.68 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.63 | 2023 | Austedo Xr |
| Allergan, INC. | $26.02 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $22.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.41 | 2025 | Relistor |
| Pfizer INC. | $15.82 | 2019 | |
| Biogen, INC. | $14.25 | 2022 | |
| Dynasplint Systems INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Tastard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.